巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Predictive Oncology

    POAI
    0.435
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Predictive Oncology - 延遲價格・最後更新於 15/08 22:00
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    0.435
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    34.11
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    1.466 - 0.249
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Predictive Oncology
    證券代碼
    POAI.US
    所屬板塊
    Medical Instruments & Supplies
    公司業務
    Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
    發行量
    65911001
    公司總部
    2915 Commers Drive, Suite 900
    公司網址
    https://www.predictive-oncology.com
    公司電話
    +1 651 389-4800
    暫無內容

    關於

    Predictive Oncology(POAI.US)所屬的行業板塊為Medical Instruments & Supplies。
    Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
    詳細公司背景可參考: https://www.predictive-oncology.com